Using targeted therapies with radiation to treat HPV-related oropharyngeal cancer
Combining BET protein inhibitors with radiation in HPV oropharyngeal cancer
This study is exploring a new way to treat oropharyngeal cancer linked to HPV by using a combination of targeted therapies and radiation to help reduce side effects and improve the treatment experience for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-10751026 on NIH RePORTER |
What this research studies
This research investigates a new approach to treating oropharyngeal cancer caused by HPV by combining targeted therapies with radiation. The goal is to reduce the side effects associated with traditional treatments like cisplatin and radiation. By using specific inhibitors that target a protein called BRD4, the research aims to make cancer cells more vulnerable to radiation, potentially leading to better outcomes for patients. This innovative method seeks to improve the quality of life for those affected by this type of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with HPV-related oropharyngeal cancer who are seeking alternative treatment options.
Not a fit: Patients with non-HPV-related oropharyngeal cancer or those who have already undergone extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatment options for patients with HPV-related oropharyngeal cancer.
How similar studies have performed: Other research has shown promise in using targeted therapies in combination with radiation for various cancers, suggesting that this approach may be effective.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Iyer, Gopal — University of Wisconsin-Madison
- Study coordinator: Iyer, Gopal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.